IP Library › Granted Patent US 9,868,718
Granted Patent B2
US 9,868,718 · App. 14/502,532 · Granted Jan 16, 2018

Cycloalkylamines as monoamine reuptake inhibitors

Inventors: Liming Shao (Lincoln, MA); Fengjiang Wang (Northborough, MA); Scott Christopher Malcolm (Southborough, MA); Michael Charles Hewitt (Somerville, MA); Larry R. Bush (Worcester, MA); Jianguo Ma (Natick, MA); Mark A. Varney (Laguna Nigel, CA); Una Campbell (Marlborough, MA); Sharon Rae Engel (Hudson, MA); Larry Wendell Hardy (Sturbridge, MA); Patrick Koch (Marlborough, MA); John E. Campbell (Waban, MA)
Assignee: Sunovion Pharmaceuticals Inc.
C07D333/20C07C211/17C07C211/29C07C211/40C07C215/42C07C215/44C07C217/52C07C217/74C07C323/32C07D207/06C07D207/08C07D211/14C07D211/16C07D265/14C07D277/28C07D295/06C07D307/52C07D317/58C07D317/72C07D319/06C07D491/056C07C2601/02C07C2601/08C07C2601/10C07C2601/14C07C2601/16C07C2602/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,868,718
App. No.
14/502,532
Granted
Jan 16, 2018
Kind
B2
Abstract

The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Claims (4)

1. A compound, wherein the compound is:

or any salt form, solvate, enantiomer, diastereomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.

2. A compound, wherein the compound is:

or any salt form, solvate, enantiomer, diastereomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2014
From: SHAO, LIMING; WANG, FENGJIANG; MALCOLM, SCOTT CHRISTOPHER; HEWITT, MICHAEL CHARLES; BUSH, LARRY R.; MA, JIANGUO; VARNEY, MARK A.; CAMPBELL, UNA; ENGEL, SHARON RAE; HARDY, LARRY WENDELL; KOCH, PATRICK; CAMPBELL, JOHN E.
To: SEPRACOR INC.
Reel/Frame 034046/0264 →
CHANGE OF NAME Recorded Oct 28, 2014
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 034067/0277 →
Continuity (4)
Continuation 12688474 · Jan 15, 2010
Continuation 11649927 · Jan 5, 2007
Provisional Application 60756550 · Jan 6, 2006
Related Publication 20150126511A1 · May 7, 2015